This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (26)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Women's Health  • Menopause  • Alert me on articles by topic  Social Bookmarking   What's this?

Diane Altkorn, MD; Tamara Vokes, MD

JAMA. 2001;285:1415-1418.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Postmenopausal osteoporosis is a common and serious clinical problem. As both individuals and society have come to recognize the importance of preventing and treating osteoporosis, several new medications have been developed that have been shown to reduce fracture rates in women with osteoporosis. This article will review recent studies and evaluate the currently available treatments for osteoporosis.

All women with low bone mineral density (BMD) should ingest 1200 to 1500 mg of calcium and 400 to 800 IU of vitamin D daily.¹ The National Osteoporosis Foundation recommends pharmacological treatment of all postmenopausal women with T scores (the number of SDs below peak young adult bone mass) below -2.0, and those with T scores below -1.5 and risk factors for osteoporosis.¹ However, for the same level of BMD, the fracture risk is much greater in older than in younger subjects.² Furthermore, the greatest benefit in . . . [Full Text of this Article]

Hormone Replacement Therapy

Selective Estrogen Receptor Modulators

Bisphosphonates

Combination Therapy and Comparison of Bisphosphonates and Estrogen

Calcitonin

Monitoring Therapy

Future Directions

Summary

Author Affiliations: Sections of General Internal Medicine (Dr Altkorn) and Endocrinology (Dr Vokes), Department of Medicine, University of Chicago, Chicago, Ill.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Association between oestrogen receptor {alpha} gene polymorphism and mortality in female end-stage renal disease patients
Kato et al.
Nephrol Dial Transplant 2007;22:2571-2577.
ABSTRACT | FULL TEXT  

National Trends in Osteoporosis Visits and Osteoporosis Treatment, 1988-2003
Stafford et al.
Arch Intern Med 2004;164:1525-1530.
ABSTRACT | FULL TEXT  

Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes
Palomba et al.
Hum Reprod 2003;18:192-198.
ABSTRACT | FULL TEXT  

COPD and Osteoporosis
Biskobing
Chest 2002;121:609-620.
ABSTRACT | FULL TEXT  

Practice Watch: Treating Postmenopausal Osteoporosis
JWatch Women's Health 2001;2001:2-2.
FULL TEXT